Tonix Pharmaceuticals Holding Corp.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
TNXP$4.10-8.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated balance sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated statements of operations for the years ended December 31, 2024 and 2023 | F-4 |
| Consolidated statements of comprehensive loss for the years ended December 31, 2024 and 2023 | F-5 |
| Consolidated statements of stockholders’ equity for the years ended December 31, 2024 and 2023 | F-6 – F-7 |
| Consolidated statements of cash flows for the years ended December 31, 2024 and 2023 | F-8 |
| Notes to consolidated financial statements | F-9 – F-35 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.